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Objective: Candida albicans is the primary causative agent of oral candidosis, and one of its
key  virulent attributes is considered to be its ability to produce extracellular phospholipases
that  facilitate cellular invasion. Oral candidosis can be treated with polyenes, and azoles,
and  the more recently introduced echinocandins. However, once administered, the intraoral
concentration of these drugs tend to be sub-therapeutic and rather transient due to factors
such as the diluent effect of saliva and cleansing effect of the oral musculature. Hence,
intra-orally, the pathogenic yeasts may undergo a brief exposure to antifungal drugs. We,
therefore, evaluated the phospholipase production of oral C. albicans isolates following brief
exposure to sub-therapeutic concentrations of the foregoing antifungals.
Materials and methods: Fifty C. albicans oral isolates obtained from smokers, diabetics, asth-
matics using steroid inhalers, partial denture wearers and healthy individuals were exposed
to  sub-therapeutic concentrations of nystatin, amphotericin B, caspofungin, ketoconazole
and  ﬂuconazole for one hour. Thereafter the drugs were removed and the phospholipase
production was determined by a plate assay using an egg yolk-agar medium.
Results: The phospholipase production of these isolates was signiﬁcantly suppressed with a
percentage reduction of 10.65, 12.14, 11.45 and 6.40% following exposure to nystatin, ampho-
tericin B, caspofungin and ketoconazole, respectively. This suppression was not signiﬁcant
following exposure to ﬂuconazole.
Conclusions: Despite the sub-therapeutic, intra oral, bioavailability of polyenes, echinocan-
dins and ketoconazole, they are likely to produce a persistent antifungal effect by
suppressing phospholipase production, which is a key virulent attribute of this common
pathogenic yeast.© 2016 Sociedade Bras
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Introduction
Candida albicans is renowned as the leading fungal pathogen of
oral candidosis, which manifests in a variety of clinical guises
ranging from common denture associated infections in oth-
erwise healthy individuals to systemic infections in human
immunodeﬁciency virus disease.1 In addition C. albicans and
several other Candida species cause recalcitrant infections in
diabetics, asthmatics using inhalation steroids, smokers and
those on cytotoxic drugs and irradiation therapy.1–4
C albicans isolates possess intriguing virulence attributes
that confer them the ability to colonize epithelial cells, adhere
and develop bioﬁlms on denture materials, and invade deeper
layers of the host epithelium. One of these, is its ability to
secrete potent extracellular phospholipases, which degrade
phospholipid constituents of the host cell membrane lead-
ing to cell disruption and subsequent epithelial invasion in
certain circumstances.5 In fact a positive correlation between
phospholipase activity and two major pathogenic attributes
of Candida has been documented, where it was shown that
C. albicans strains with the highest phospholipase activity
exhibited the highest adherence to oral epithelial cells and
a greatest ability to kill mice after intravenous inoculation,
compared with yeasts with a low degree of phospholipase
activity.5
A number of antifungal therapeutic agents are available
for treatment of Candida infections, including oral candido-
sis. These include the two polyenes group agents, nystatin and
amphotericin B, the echinocandins agent caspofungin and the
azoles such as ketoconazole (an imidazole) and ﬂuconazole (a
triazole).1,6 Despite the availability of these therapeutic agents
for the management of oral candidosis, failure of therapy and
resultant recalcitrant infection is not uncommon.6 One rea-
son for this may be the unique nature of the oral milieu where
the diluent effect of saliva and the cleansing effect of the oral
musculature tend to reduce the bioavailability of antifungal
agents below that of the effective therapeutic concentrations.
Hence, intra-orally, the pathogenic Candida may undergo a
brief exposure to a high concentration of the antifungal agent
on administration, and thereafter the drug concentration is
likely to be sub-therapeutic.6
There is a single study that documents the impact of brief
exposure to three antifungal agents (i.e. nystatin, ampho-
tericin B and ﬂuconazole) on extracellular phospholipase
production of ten oral C. albicans isolates from HIV-infected
individuals.7 Yet, the phospholipase production of oral C.
albicans isolates obtained from susceptible patient groups such
as diabetics, asthmatics using inhalation steroids, smokers
and partial denture wearers following brief exposure to sub-
therapeutic concentrations of antifungals with a different
array of pharmacodynamics has not been studied thus far.
Though, all the aforementioned antifungal agents are not
used as topically administered formulations, such prepara-
tions could be formulated for future use in the management of
oral candidosis. Therefore, taken together the aforementioned
information, the main aim of this investigation was to deter-
mine the extracellular phospholipase production of 50 oral
C. albicans isolates obtained from diabetics (n = 10), asthmat-
ics using inhalation steroids (n = 10), smokers (n = 10), partial b i o l o g y 4 7 (2 0 1 6) 911–916
acrylic denture wearers (n = 10), and healthy individuals (n = 10)
following their brief exposure to nystatin, amphotericin B,
caspofungin, ketoconazole and ﬂuconazole.
Materials  and  methods
Organisms
A total of 50 oral isolates of C. albicans recovered from oral
rinse samples from patients attending the Kuwait University
Dental Clinic (KUDC) for dental treatment in a previous study
were included in the current study (10 isolates each were
from smokers, diabetics, asthmatics using steroid inhala-
tion, patients wearing partial acrylic dentures and healthy
individuals).8 The healthy group were patients seeking den-
tal treatment who were otherwise healthy with no medical
condition or medication at the time of collecting the oral
rinse samples. The diabetic patients were under oral hypogly-
caemic drugs and the asthmatic patients were under steroid
inhalation therapy, and were otherwise healthy at the time of
attending the dental clinics. The patients who  smoked more
than 25 cigarettes per day were considered as smokers. Den-
ture wearers were using partial removable acrylic dentures
for a period of more  than 6 months. None of the patients
from whom the isolates were recovered had oral candidosis or
any other systemic illness. Initially, all the yeast isolates were
tested for germ tube formation. Thereafter the colony char-
acteristics were observed using CHROMagar Candida medium
(Becton Dickinson and Company, Sparks, USA) and identiﬁed
by VITEK 2 yeast ID system (BioMérieux, France) as well as API
20C AUX yeast ID system (BioMérieux, Inc, Hazelwood, MO).
Antifungal  agents  and  media
Antifungal agents was prepared as done previously in sim-
ilar studies.9 Brieﬂy, nystatin, amphotericin B, ketoconazole
and ﬂuconazole (Sigma, St. Louis, MO, USA) were dissolved in
dimethylsulphoxide (DMSO). Caspofungin (Merck and Com-
pany Inc, Waterhouse Station, NJ, USA) was dissolved in sterile
distilled water. These antimycotic agents were prepared ini-
tially as 10,000 g/mL and stored at −20 ◦C prior to each
experiment as previously described.9 It was thereafter sus-
pended/diluted in the following medium during the exposure
period (1 h) of yeasts. RPMI 1640 medium buffered with 0.165 M
MOPS (3-(N-morpholino) propanesulfonic acid) containing l-
glutamine and lacking sodium bicarbonate (Sigma, USA), was
dissolved in 1 l of sterile distilled water and adjusted to a pH
of 7.2 and ﬁlter sterilized.
Determination  of  minimal  inhibitory  concentration
Minimum inhibitory concentration (MIC) values against
amphotericin B, caspofungin, ketoconazole and ﬂuconazole
were determined by E test, performed according to the man-
ufacturer’s recommendations (AB BIODISK, Solna, Sweden)
as described previously.8 Freshly sub-cultured isolates (ﬁve
colonies) were uniformly suspended in sterile saline, and tur-
bidity was adjusted to 0.5 McFarland standard. The McFarland
Standard 0.5 is approximately equal to 1 × 106–5 × 106 cells/mL
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Clinical and Laboratory Standards Institute, CLSI M44-A,
004). This inoculum was swabbed onto the agar plates
150 mm diameter) and allowed to dry for 10–15 min  before
he E test strips were applied. RPMI 1640 agar supplemented
ith 2% glucose and buffered with MOPS (0.165 M; pH 7.0)
as used for susceptibility testing according to the method
ecommended by the Clinical and Laboratory Standards Insti-
ute (formerly National Committee for Clinical Laboratory
tandards; M27-A2). The plates were incubated at 35 ◦C, and
inimum inhibitory concentrations (MIC) were read after
4–48 h of incubation. The point where inhibition ellipses
ntercepted the scale on the antifungal strip was taken as
he MIC  for each test isolate: complete inhibition (100%) of
rowth for amphotericin B and caspofungin, and marked
ecrease in growth intensity (80%) for ﬂuconazole and keto-
onazole. Reference strains of C. albicans, ATCC 90028, and C.
arapsilosis, ATCC 22019, were used for quality control of the
usceptibility testing. Interpretive susceptibility breakpoints
or ﬂuconazole were those recommended by Clinical and Lab-
ratory Standards Institute document M27-A2. Due to the
ack of deﬁned susceptibility breakpoints for amphotericin
 and ketoconazole, an isolate was considered susceptible
ith an MIC  breakpoint of ≤1.0 g/mL for amphotericin B and
.125 g/mL for ketoconazole. For caspofungin, isolates with
IC  of ≤2.0 g/mL were considered as susceptible.
The MIC  values of nystatin were determined by the broth
ilution technique by performing two-fold serial dilutions of
he drug in microtitre plates using an inoculum of 1–5 × 105
olony forming units (CFU)/mL, as done previously.9 The MIC
as determined visually following 24 h incubation at 37 ◦C.
he MIC  was deﬁned as the lowest concentration of the drug
hat inhibited growth of Candida cells, as indicated by the
bsence of turbidity (optically clear). The MIC  was read inde-
endently by two laboratory personals. C. albicans ATCC 90028
as used as a reference strain.
reparation  of  cell  suspension  for  the  phospholipase
roduction  assay
 previously described method was used for this purpose.10
rieﬂy, yeast cells maintained on Sabouraud’s dextrose agar
SDA), were inoculated onto fresh plates and incubated
vernight at 37 ◦C for 24 h prior to use. The organisms were
arvested and a cell suspension prepared in sterile phosphate
uffered saline (PBS) at 520 nm to an optical density of 1.5.
rom this cell suspension, 0.5 mL  was added to tubes contain-
ng 2 mL  of PBS (control) and 2 mL  of PBS/antifungal agent
2 MIC  (test). This gave a cell suspension of 106 cells mL−1
n each assay tube. The tubes were then incubated at 37 ◦C
or a period of 30 min. Following this limited exposure, the
rugs were removed by two cycles of dilution with sterile PBS
nd centrifugation for 10 min  at 3000 × g (gravity). Afterwards
he supernatant was completely decanted and the pellets
ere re-suspended in 2.5 mL  of sterile PBS. This procedure
as been used previously for drug removal and has shown
o reduce the concentration of the drug as much as 10,000
old, thereby minimizing any carry-over effect of the drug fol-
owing its removal.7,9–12 Viable counts of the control and the
est were performed after drug removal. As the procedure
f drug removal effectively eliminated any carry-over effecto l o g y 4 7 (2 0 1 6) 911–916 913
there was virtually no difference on the viable counts of the
control and the tests following exposure to already diluted
sub-therapeutic concentrations of the drug. In addition, under
Gram-stain, Gram-positive yeast cells were seen when Candida
were observed under light microscopy before brief exposure to
these antifungals and did not reveal any observable changes
soon after removal of these drugs (i.e. before the phospholi-
pase production assays were performed) compared to the cells
observed before the exposure.
Phospholipase  production  assay  (egg  yolk  agar  method)
C. albicans isolates were screened for phospholipase activity
by growing the isolates on egg yolk medium and measur-
ing the size of the zone of precipitation (i.e. production of
phospholipase) as done in previous studies.7,10,13,14 The egg
York medium consisted of Sabouraud’s dextrose agar, 13.0 g;
NaCl, 11.7 g; CaCl2, 0.11 g; and 10% sterile egg yolk emulsion
in 184 mL  of distilled water. The egg yolk emulsion was cen-
trifuged at 500 × g for 10 min at room temperature, and 20 mL
of the supernatant was added to the cooled sterilized medium.
A 10 L suspension of 107 yeast cells (drug-exposed and con-
trol) per mL  in PBS was plated on the surface of egg yolk
medium in a 90 mm diameter petridish and left to dry at room
temperature. The plates were then incubated at 37 ◦C for 72 h.
The phospholipase activity (Pz index) of the isolates was inter-
preted positive when a precipitation zone was visible around
the growth and the value of phospholipase production was
determined by the ratio of the diameter of the colony plus
the precipitation zone to the diameter of the colony as done
previously.7,10,13
All experiments were repeated on three separate occasions
with duplicate determinations on each occasion.
Statistical  analysis
The data obtained from the phospholipase assay was ana-
lyzed using ANOVA Dunnett’s t-tests, which treat one group
as a control (unexposed to drugs), and compare the other
group (exposed to drugs) against it. In addition the variations
between the effects of antifungal drugs from each other on the
suppressive effect on phospholipase production was analyzed
using Tukey–Kramer Multiple Comparative tests. A p value of
<0.05 was considered statistically signiﬁcant.
Results
All C. albicans isolates were susceptible to the antifungal drugs
tested. The MIC (g/mL) values of all C. albicans isolates for nys-
tatin obtained from the broth dilution technique ranged from
0.78 to 1.56. The MIC values obtained by E-tests for ampho-
tericin B was between 0.004 and 0.19 and for caspofungin it
ranged from 0.004 to 0.125. Ketoconazole elicited a MIC  of
0.004–0.032 while it ranged between 0.047 and 0.125 for ﬂu-
conazole.Mean phospholipase production (as Pz index) of the 50 C.
albicans isolates, following limited exposure to ﬁve different
antifungal drugs, drug removal and subsequent produc-
tion of phospholipase activity is shown in Table 1. Mean
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Table 1 – Mean (±SEM) phospholipase activity (Pz index) of 50 oral C. albicans isolates following 1 h exposure and
subsequent removal of ﬁve different antifungal drugs. Each value indicates the mean (±SEM) phospholipase activity of 10
oral C. albicans obtained either from healthy individuals, diabetic patients, asthmatic patients, smokers or denture
wearers. SEM, standard error of mean; SD, standard deviation.
Source of C. albicans isolates (n = 50) Unexposed controls Nystatin Amphotericin B Caspofungin Ketoconazole Fluconazole
Healthy 1.75 1.54 1.50 1.52 1.64 1.73
(n = 10) (0.03) (0.02) (0.02) (0.02) (0.02) (0.03)
SD 0.10 0.06 0.07 0.06 0.06 0.10
Diabetic 1.76 1.59 1.55 1.57 1.65 1.74
(n = 10) (0.03) (0.02) (0.02) (0.02) (0.01) (0.03)
SD 0.10 0.07 0.06 0.07 0.04 0.09
Asthmatic 1.78 1.59 1.58 1.58 1.63 1.76
(n = 10) (0.03) (0.02) (0.02) (0.02) (0.02) (0.03)
SD 0.09 0.06 0.07 0.05 0.05 0.09
Smokers 1.73 1.54 1.52 1.53 1.63 1.72
(n = 10) (0.02) (0.02) (0.02) (0.02) (0.02) (0.02)
SD 0.07 0.07 0.07 0.06 0.06 0.07
Denture wearers 1.71 1.54 1.52 1.53 1.62 1.69
(n = 10) (0.02) (0.02) (0.02) (0.02) (0.02) (0.02)
SD 0.05 0.05 0.05 0.06 0.06 0.05
Mean 1.75 1.56 1.54 1.55 1.63 1.73
(±SEM) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01)
SD 0.08 0.06 0.07 0.06 0.05 0.08
p value <0.001 <0.001 <0.001 <0.001 NS
Table 2 – Summary of the mean percentage suppression of phospholipase production in 50 oral C. albicans isolates
following 1 h exposure and subsequent removal of ﬁve different antifungal drugs. Each value indicates the mean
percentage reduction of phospholipase production in 10 oral C. albicans obtained from either healthy individuals,
diabetic patients, asthmatic patients, smokers or denture wearers. SEM, standard error of mean; SD, standard deviation.
Source of C. albicans
Isolates (n = 50)
Nystatin Amphotericin B Caspofungin Ketoconazole Fluconazole
Healthy (n = 10) 12.00 14.29 13.14 6.29 1.14
Diabetic (n = 10) 9.66 11.93 10.80 6.25 1.14
Asthmatic (n = 10) 10.67 11.24 11.24 8.43 1.12
Smokers (n = 10) 10.98 12.14 11.56 5.78 0.58
Denture wearers (n = 10) 9.94 11.11 10.53 5.26 1.17
Mean 10.65 12.14 11.45 6.40 1.03
SEM 0.41 0.57 0.46 0.54 0.11
combination of both are associated with the pathogenesis ofSD 0.92 1.28 
p value <0.001 <0.001 
phospholipase production of the unexposed isolates was 1.75,
whereas this ﬁgure following exposure to nystatin, ampho-
tericin B, caspofungin, ketoconazole and ﬂuconazole was 1.56,
1.54, 1.55, 1.64 and 1.73, respectively. Hence, as shown in
Table 2, a signiﬁcant reduction of phospholipase activity was
seen following exposure to nystatin, amphotericin B, caspo-
fungin and ketoconazole, with a mean percentage reduction
of 10.65%, 12.14%, 11.45% and 6.40%, respectively. Overall sup-
pressive effect on the phospholipase production following
exposure to ﬂuconazole was not signiﬁcant in comparison to
the unexposed control.
As shown in Table 3, analysis of the variation between
the ﬁve drugs on the suppression of phospholipase produc-
tion using Tukey–Kramer multiple comparative tests revealed
that the suppressive effect elicited by the polyene and
echinocandin antifungal agents were signiﬁcantly higher
and statistically different from that of the two azole drugs
(p < 0.001). In addition, the suppressive effect elicited by the1.02 1.21 0.25
<0.001 <0.001 NS
two azoles was also statistically different from each other
(p < 0.005). However, the suppressive effect elicited by the two
polyenes and the echinocandin agent was not signiﬁcantly
different.
Discussion
A wide array of exquisite and speciﬁc attributes is required
for a pathogenic organism to penetrate the eukaryotic epithe-
lial cell barrier of the human host. It is well known that
the ﬁlamentous candidal hyphae are critical in this process
and these together with the extracellular phospholipases of
the fungus facilitate the yeast invasion of the host tissues.
Clearly, therefore, both physical or enzymatic activity or acandidal disease. As phospholipids are a foremost constituent
of the host cell envelope, enzymes capable of hydrolyzing
phospholipids i.e. phospholipases, are likely to play a critical
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Table 3 – Statistical analysis by Tukey–Kramer multiple comparison test on the comparison of the relative efﬁcacy of ﬁve
different agents in reducing phospholipase production of C. albicans isolates.
Drug Nystatin Amphotericin B Caspofungin Ketoconazole Fluconazole
Nystatin – NS NS p < 0.001 p < 0.001
Amphotericin B NS – NS p < 0.001 p < 0.001
Caspofungin NS NS – p < 0.001 p < 0.001
Ketoconazole p < 0.001 p < 0.001 p < 0.001 – p < 0.001
Fluconazole p < 0.001 p < 0.001 p < 0.001 p < 0.001 –
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gNS, difference on the adhesion suppressive effect between the drugs
ole in host cell invasion. By cleaving phospholipids, candidal
hospholipases undermine the membrane and cell lysis is the
nd result.15
Amongst the various Candida species, C. albicans is by far
he major aetiological agent associated with oral candido-
is and its superior phospholipase activity in comparison
o other non-albicans Candida species, is considered to be
ne reason for its relatively high virulence amongst its
eers.7,15
There is scarcity of data on the impact of antimycotic
gents on phospholipase production of oral C. albicans. Hence,
e attempted to study the impact of polyenes (nystatin
nd amphotericin B), echinocandins (caspofungin) and azoles
ketoconazole and ﬂuconazole) on phospholipase production
f oral C. albicans obtained from different patient groups. Our
ata indicate that the, exposure of oral C. albicans isolates to
ub-MIC concentrations of all the tested drugs signiﬁcantly
uppressed phospholipase production with the exception of
uconazole.
The select group of agents we chose to study, exerts
heir antifungal activity through different pharmacodynamics
echanisms. Polyenes, for instance bind to the sterol compo-
ents in the yeast cell wall and make it more  permeable.1,6
t has also been advocated that the formation of sterols or
heir precursors may also be repressed by the polyenes.1,6
urthermore, studies have shown internally collapsed cells
ith an intact cell wall leaving “ghosts-like” cells and deﬂated
andida cells following exposure to sub-cidal concentrations
f polyenes.11 Caspofungin, on the contrary, acts by inhibi-
ing the enzyme responsible for biosynthesis of -1,3 glucan
esulting in disturbing the integrity of the fungal cell wall.16 In
ddition caspofungin has shown excellent growth-inhibitory
ctivity against Candida at low concentrations.16 As for keto-
onazole, it alters the fungal cell membranes by blocking the
4 -demethylation step in the biosynthesis of ergosterol.
he consequent depletion of ergosterol and accumulation
f 14 -methyl-sterols leads to alterations in a number of
embrane-associated functions.1,6 Considering the forego-
ng wide range pharmacodynamic properties of the agents
e have studied it is tempting to speculate that the struc-
ural changes of the cell wall as well as the metabolic effects
licited by the drugs would all contribute to the suppression of
east phospholipase activity we  have described in the current
tudy. In this context it is noteworthy that a previous study
as also implied that the drug-induced metabolic changes
n suppressing phospholipase production persisted into the
ubsequent progeny of daughter yeasts and not the parent
eneration of cells exposed to antifungals, due to the fact thatnot signiﬁcant.
phospholipase activity is determined after 72 h of incubation.7
The current results also tend to augment and conﬁrm these
previous observations.
The signiﬁcant difference between polyenes and
echinocandins with that of azoles on the suppressive effect
on phospholipase production of Candida as seen in this study
may well be due to the differences in the pharmacodynamics
of the antimycotic groups. Polyenes and echinocandins
are fungicidal against C. albicans isolates whereas azoles
are fungistatic.1,6,16 This could be the main reason for the
exquisite sensitivity of the cell-surface structures of C. albicans
to nystatin, amphotericin B and caspofungin compared to
the azoles. In addition to the aforementioned difference, a
signiﬁcant difference in the suppressive effect on phospho-
lipase production was also seen between the two  azoles.
Though ﬂuconazole is remarkably more  effective than keto-
conazole in the management of candidal infection, its growth
inhibitory activity against C. albicans isolates in vitro is much
less than that of ketoconazole.6,9,17 Furthermore, there could
be subtle changes in the pharmacodynamics between the
two azoles, ketoconazole being a imidazole and ﬂuconazole
being a triazole. Therefore, though not conclusive, it is likely
that the differences in the mode of activity between the two
azoles may be the reasons for ﬂuconazole not eliciting a
signiﬁcant suppression of phospholipase production of C.
albicans isolates tested.
When the phospholipase production of C. albicans isolates
obtained from different patient groups were compared follow-
ing exposure to antifungal drugs as well as of the unexposed
control isolates there was no signiﬁcant difference amongst
the isolates, indicating that the phospholipase production of
all the isolates were quite uniform with or without exposure
to the drugs, at least in this study.
Taken together, the foregoing data contributes further
to the understanding of the pharmacodynamics of these
antimycotics in relation extracellular phospholipase pro-
duction of C. albicans, which frequently colonizes and cause
oral disease in diabetics, asthmatics using steroid inhalers,
smokers and denture wearers. While the precise clinical
signiﬁcance of these antimycotics in modulating Candida
phospholipase production cannot be ascertain, it could
be argued that these drugs are capable disarming Candida
virulence by suppressing phospholipase production, in addi-
tion to their other antifungal pharmacodynamics. To our
knowledge this is the ﬁrst study to document the impact of
antimycotic agents with a wider array of pharmacodynamics
properties (i.e. polyene, echinocandin, imidazole and triazole)
on phospholipase production, of oral C. albicans isolates
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obtained from a diverse group of individuals from a single
geographic locale. The exact cellular mechanisms underlying
our observations, however, remain to be elucidated.
Conclusions
Brief and transient exposure to sub-therapeutic concentra-
tions of antimycotics may modulate phospholipase produc-
tion of C. albicans isolates in vitro, thereby possibly quelling its
pathogenicity.
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